Latest Series C+ Funding Rounds
Later-stage rounds, from Series C onwards, for companies expanding products, distribution and operations.
- Rounds
- 572 All time
- Disclosed funding
- $283.5B 494 disclosed amounts
- Median round
- $126M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| o osapiensCompany profile Provides enterprise software for sustainable growth and regulatory compliance Provides enterprise software for sustainable growth and regulatory compliance | $100M | Series CSeries C+ | Enterprise software | Germany | Investors | |
| Q QuadricCompany profile Quadric is a licensor of fully programmable general-purpose AI inference processor IP Quadric is a licensor of fully programmable general-purpose AI inference processor IP | $30M | Series CSeries C+ | AI | United States | Investors | |
AlpacaCompany profile Brokerage APIs and custody infrastructure that let financial businesses embed investing and trading into their own products. Brokerage APIs and custody infrastructure that let financial businesses embed investing and trading into their own products. | $150M | Series DSeries C+ | Fintech | United States | Investors | |
| O AI-powered platform for military command and operations | $200M | Series DSeries C+ | Defense tech | United States | Investors | |
| N NucleraCompany profile Provides rapid access to functional proteins through benchtop eProtein Discovery System Provides rapid access to functional proteins through benchtop eProtein Discovery System | $12M | Series C+ | Biotech | United Kingdom | Investors | |
DeepgramCompany profile Deepgram provides real-time voice APIs for speech recognition, speech synthesis and voice AI applications. Deepgram provides real-time voice APIs for speech recognition, speech synthesis and voice AI applications. | $130M | Series CSeries C+ | AI | United States | Investors | |
| OT Oricell TherapeuticsCompany profile Develops next-generation cell therapies for oncology and immunology Develops next-generation cell therapies for oncology and immunology | $70M | Series C1Series C+ | Biotech | China | Investors | |
| IM Inquis MedicalCompany profile Develops mechanical thrombectomy systems for venous thromboembolic disease Develops mechanical thrombectomy systems for venous thromboembolic disease | $75M | Series CSeries C+ | Healthtech | United States | Investors Undisclosed | |
| T TorqCompany profile Empowers enterprises to instantly and precisely detect and respond to security events at scale Empowers enterprises to instantly and precisely detect and respond to security events at scale | $140M | Series DSeries C+ | Cybersecurity | United States | Investors | |
| R Provides enterprise-grade infrastructure for stablecoin-powered payments | $250M | Series CSeries C+ | Fintech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1Andreessen Horowitz (a16z)
Isomorphic Labs, Northwood Space, Kalshi
44rounds5led - 2General Catalyst
Mercor, Clara, Nominal
44rounds1led - 3Sequoia Capital
Isomorphic Labs, LangChain, Nominal
43rounds8led - 4Lightspeed
Payhawk, Nominal, Fractile
39rounds7led - 5NVIDIA
Agile Robots, Mercor, fal
36rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.